These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 30149180)

  • 1. The glycoprotein GPNMB is selectively elevated in the substantia nigra of Parkinson's disease patients and increases after lysosomal stress.
    Moloney EB; Moskites A; Ferrari EJ; Isacson O; Hallett PJ
    Neurobiol Dis; 2018 Dec; 120():1-11. PubMed ID: 30149180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell type-specific lipid storage changes in Parkinson's disease patient brains are recapitulated by experimental glycolipid disturbance.
    Brekk OR; Honey JR; Lee S; Hallett PJ; Isacson O
    Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27646-27654. PubMed ID: 33060302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective loss of glucocerebrosidase activity in sporadic Parkinson's disease and dementia with Lewy bodies.
    Chiasserini D; Paciotti S; Eusebi P; Persichetti E; Tasegian A; Kurzawa-Akanbi M; Chinnery PF; Morris CM; Calabresi P; Parnetti L; Beccari T
    Mol Neurodegener; 2015 Mar; 10():15. PubMed ID: 25881142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains.
    Gegg ME; Burke D; Heales SJ; Cooper JM; Hardy J; Wood NW; Schapira AH
    Ann Neurol; 2012 Sep; 72(3):455-63. PubMed ID: 23034917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson's disease.
    Huebecker M; Moloney EB; van der Spoel AC; Priestman DA; Isacson O; Hallett PJ; Platt FM
    Mol Neurodegener; 2019 Nov; 14(1):40. PubMed ID: 31703585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The lysosomal β-glucocerebrosidase strikes mitochondria: implications for Parkinson's therapeutics.
    Rubilar JC; Outeiro TF; Klein AD
    Brain; 2024 Aug; 147(8):2610-2620. PubMed ID: 38437875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic ablation of Gpnmb does not alter synuclein-related pathology.
    Brendza R; Lin H; Stark K; Foreman O; Tao J; Pierce A; Ngu H; Shen K; Easton AE; Bhangale T; Chang D; Bingol B; Friedman BA
    Neurobiol Dis; 2021 Nov; 159():105494. PubMed ID: 34464706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
    Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
    J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The glycoprotein GPNMB attenuates astrocyte inflammatory responses through the CD44 receptor.
    Neal ML; Boyle AM; Budge KM; Safadi FF; Richardson JR
    J Neuroinflammation; 2018 Mar; 15(1):73. PubMed ID: 29519253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of Brain Lysosomal Activities in GBA-Related and Sporadic Parkinson's Disease and Dementia with Lewy Bodies.
    Moors TE; Paciotti S; Ingrassia A; Quadri M; Breedveld G; Tasegian A; Chiasserini D; Eusebi P; Duran-Pacheco G; Kremer T; Calabresi P; Bonifati V; Parnetti L; Beccari T; van de Berg WDJ
    Mol Neurobiol; 2019 Feb; 56(2):1344-1355. PubMed ID: 29948939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycosphingolipid levels and glucocerebrosidase activity are altered in normal aging of the mouse brain.
    Hallett PJ; Huebecker M; Brekk OR; Moloney EB; Rocha EM; Priestman DA; Platt FM; Isacson O
    Neurobiol Aging; 2018 Jul; 67():189-200. PubMed ID: 29735433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy.
    Cosden M; Jinn S; Yao L; Gretzula CA; Kandebo M; Toolan D; Hatcher NG; Ma L; Lemaire W; Adam GC; Burlein C; Minnick C; Flick R; Watt ML; Mulhearn J; Fraley M; Drolet RE; Marcus JN; Smith SM
    Neurobiol Dis; 2021 Nov; 159():105507. PubMed ID: 34509608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole Transcriptome Analysis of Substantia Nigra in Mice with MPTP-Induced Parkinsonism Bearing Defective Glucocerebrosidase Activity.
    Usenko T; Bezrukova A; Rudenok MM; Basharova K; Shadrina MI; Slominsky PA; Zakharova E; Pchelina S
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Path mediation analysis reveals GBA impacts Lewy body disease status by increasing α-synuclein levels.
    Gündner AL; Duran-Pacheco G; Zimmermann S; Ruf I; Moors T; Baumann K; Jagasia R; van de Berg WDJ; Kremer T
    Neurobiol Dis; 2019 Jan; 121():205-213. PubMed ID: 30236861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cav1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons.
    Dragicevic E; Poetschke C; Duda J; Schlaudraff F; Lammel S; Schiemann J; Fauler M; Hetzel A; Watanabe M; Lujan R; Malenka RC; Striessnig J; Liss B
    Brain; 2014 Aug; 137(Pt 8):2287-302. PubMed ID: 24934288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glial reactions in Parkinson's disease.
    McGeer PL; McGeer EG
    Mov Disord; 2008 Mar; 23(4):474-83. PubMed ID: 18044695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson's disease patients.
    Doorn KJ; Moors T; Drukarch B; van de Berg WDj; Lucassen PJ; van Dam AM
    Acta Neuropathol Commun; 2014 Aug; 2():90. PubMed ID: 25099483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repulsive Guidance Molecule a (RGMa) Induces Neuropathological and Behavioral Changes That Closely Resemble Parkinson's Disease.
    Korecka JA; Moloney EB; Eggers R; Hobo B; Scheffer S; Ras-Verloop N; Pasterkamp RJ; Swaab DF; Smit AB; van Kesteren RE; Bossers K; Verhaagen J
    J Neurosci; 2017 Sep; 37(39):9361-9379. PubMed ID: 28842419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-cell sequencing of human midbrain reveals glial activation and a Parkinson-specific neuronal state.
    Smajić S; Prada-Medina CA; Landoulsi Z; Ghelfi J; Delcambre S; Dietrich C; Jarazo J; Henck J; Balachandran S; Pachchek S; Morris CM; Antony P; Timmermann B; Sauer S; Pereira SL; Schwamborn JC; May P; Grünewald A; Spielmann M
    Brain; 2022 Apr; 145(3):964-978. PubMed ID: 34919646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibroblasts from idiopathic Parkinson's disease exhibit deficiency of lysosomal glucocerebrosidase activity associated with reduced levels of the trafficking receptor LIMP2.
    Thomas R; Moloney EB; Macbain ZK; Hallett PJ; Isacson O
    Mol Brain; 2021 Jan; 14(1):16. PubMed ID: 33468204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.